Jake Van Naarden, Loxo@Lilly CEO
Lilly enters ripe BTK field with quick FDA nod in mantle cell lymphoma
Eli Lilly has succeeded in its attempt to get the first non-covalent version of Bruton’s tyrosine kinase, or BTK, inhibitors to market, pushing it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
